AATec Medical GmbH is developing innovative therapeutic solutions for respiratory inflammatory diseases, airway infections, and rare conditions. The company’s proprietary product platform is based on a novel recombinant version of alpha-1 antitrypsin (AAT) for inhalation, a human serine protease inhibitor with broadband anti-inflammatory, immuno-modulatory and anti-infective properties. AATec Medical aims to unlock the full therapeutic potential of AAT for diseases with high medical need and limited or no available therapies.

With proof-of-principle successfully demonstrated in various preclinical studies, AATec Medical is advancing toward a proof-of-concept clinical trial with the lead product candidate, ATL-105, in non-cystic fibrosis bronchiectasis (NCFB), a progressive lung condition affecting millions of patients globally. ATL-105 uses cutting-edge nebulization technology for inhalation, enabling the delivery of the drug directly to the airways for optimal local effects.

Inflammatory respiratory diseases are globally on the rise due to lifestyle, environmental factors, climate change, and global migration. Conditions like COPD, bronchiectasis, asthma, acute respiratory distress syndrome (ARDS) or respiratory infections are creating significant challenges for healthcare systems worldwide. AATec Medical addresses the increasing demand for effective treatments for these diseases. The company has the aim to provide accessible and affordable therapeutics to meet these challenges, contributing to health and well-being globally.